<DOC>
	<DOCNO>NCT02376296</DOCNO>
	<brief_summary>In observational study , blood sample pharmacokinetic ( PK ) test collect subject metastatic prostate cancer treatment docetaxel . Plasma level docetaxel determine , subject docetaxel exposure level , determine area curve ( AUC ) , retrospectively correlate report toxicity , tumor response , quality life , time disease progression overall survival provide guidance appropriate target range docetaxel exposure metastatic prostate cancer subject receive docetaxel therapy disease .</brief_summary>
	<brief_title>Observational Study Docetaxel Exposure Metastatic Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis adenocarcinoma prostate . Male subject 18 year age old . About start new line treatment docetaxel ( 75 mg/m2 ) combination prednisone . All subject must inform investigational nature study willing provide write informed consent accordance Institutional guideline good clinical practice ( GCP ) indicate understand purpose procedure require study willing participate study prior begin specific study procedure . Prior surgical castration concurrent use agent chemical castration serum testosterone level &lt; 50 ng/dL . Subjects hormone naïve metastatic prostate cancer , must highvolume disease , define extranodal visceral disease bone metastases least 4 bone lesion ( one outside vertebral column pelvis ) . Subjects hormone naïve highvolume metastatic prostate adenocarcinoma must androgen deprivation therapy ( include luteinizing hormonereleasing hormone ( LHRH ) agonist therapy , LHRH antagonist therapy , surgical castration ) less 120 day prior start docetaxel therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . For subject castrate resistant prostate cancer ( CRPC ) , least four week elapse withdrawal antiandrogens ( Bicalutamide , Flutamide Nilutamide ) initiation docetaxel therapy . For subject CRPC , least four week elapse last administration Abiraterone ( Zytiga® ) Enzalutamide ( Xtandi® ) initiation docetaxel therapy . At least four week elapse prior surgery prior radiotherapy initiation docetaxel therapy . Radiographdocumented evidence soft tissue bony metastatic disease . Must adequate hematologic , hepatic renal function define : Hematologic ( minimal value ) : Absolute neutrophil count ≥ 1,500/mm3 ; Hemoglobin ≥ 10.0 g/dl ; Platelet count ≥ 75,000/mm3 Hepatic Function : Total Bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) ; asparate transaminase ( AST ) alanine transaminase ( ALT ) &lt; 2 x institutional ULN Suitable venous access healthy enough ( determine treat physician ) provide whole blood sample . Any condition / concomitant disease allow chemotherapy docetaxel , prednisone require premedication treatment regimen . Serious concurrent disorder ( active infection require intravenous antibiotic , unstable angina , uncompensated congestive heart failure ( CHF ) , hepatic failure ) , opinion investigator , would prevent use docetaxel and/or compromise subject 's ability provide whole blood sample participation study . Concurrent use nonFDA approve ( i.e . investigational experimental ) anticancer agent ( ) within four ( 4 ) week enrol study . Preexisting neuropathy ≥ grade 2 per National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) version 4 . Individuals know seropositivity human immunodeficiency virus ( HIV ) , hepatitis C virus , hepatitis B surface antigen , syphilis . Unwilling unable follow protocol requirement provide informed consent .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>metastatic prostate cancer</keyword>
	<keyword>castrate resistant prostate cancer</keyword>
	<keyword>CRPC</keyword>
	<keyword>hormone sensitive prostate cancer</keyword>
</DOC>